Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis - Summary - MDSpire
Advertisement
Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis
To evaluate the efficacy and safety of CD38-directed CAR-T therapy in patients with relapsed/refractory multiple myeloma (RRMM), comparing single-target and dual-target therapies.
Key Findings:
Pooled overall response rate (ORR) for dual-target CD38/BCMA CAR-T was 89%.
Complete response/stringent complete response (CR/sCR) rate was 63%.
Minimal residual disease (MRD)-negative rate was 67%.
Mortality rate for dual-target therapy was 11%; single-target CD38 CAR-T had a mortality rate of 44% in the studied population.
Any-grade cytokine release syndrome (CRS) occurred in 83% of patients.
Interpretation:
Dual-target CD38/BCMA CAR-T shows promising efficacy and manageable safety in RRMM, while single-target CD38 CAR-T has limited efficacy and higher mortality, suggesting a need for careful clinical consideration.
Limitations:
Small sample size with only 4 studies included.
Limited evidence for single-target CD38 CAR-T therapy, with potential biases in the included studies.
Conclusion:
Dual-target CD38/BCMA CAR-T therapy is a promising option for RRMM, but further large-scale comparative studies are needed to clarify its role in treatment sequencing and optimize patient outcomes.
